Slide 1: ASX cover letter: Presentation to Investors
Level 2, 66 Hunter H Streett Sydneyy NSW 20000 Tel: (61--2) 9300 33444 Fax: (61--2) 9221 63333 E-mail: pnigghtingale@biootron.com.au u For personal use only Webssite: www.bio otron.com.au u 25 Octoberr 2018 The Managger Compannies ASX Limitted 20 Bridge S Street Sydney NSSW 2000 (17 pagess by email)
Slide 2: Biotron Limited Investor Update October 2018
BIOTRON LIMITED For personal use only (ASX:BIT) Investor Update October 2018
Slide 3: Forward Looking Statements
Forward Looking Statements For personal use only This presentation may contain forward-looking statements with respect to the financial condition, results and business achievements/performance of Biotron Limited (ACN 086 399 144) and certain of the plans and objectives of its management. These state
Slide 4: Financial Information
Financial Information Key Financial Metrics 6 Month Share Price Performance For personal use only Ticker Code ASX: BIT Share Price (24 Oct 18) A $0.16 Ticker Code ASX: BIT Market cap A $83 million Share Price (15 Sept 2014) A $0.115 12 Month Trading Range A $0.014 - $0.445 Shares Outstanding 503 mil
Slide 5: Biotron Snapshot
Biotron Snapshot • Clinical stage drug development company For personal use only • Robust pipeline of drugs targeting serious virus infections • Lead candidate BIT225 is a novel, first-in-class, oral small molecule drug • In development for treatment of HIV-1 and Hepatitis C virus (HCV) • Positive d
Slide 6: Key Achievements 2018
Key Achievements 2018 For personal use only • Completed Phase 2 HIV-1 clinical trial of BIT225 • Reported positive outcomes from the Phase 2 HIV-1 clinical trial in Sept ’18 • Receipt of $1.07 million R&D Tax Incentive refund in Oct ‘18 • Secured $4.7 million underwriting agreement for 30 Nov ‘18 $0
Slide 7: Biotron – Antiviral-Focused Pipeline
Biotron – Antiviral-Focused Pipeline MECHANISM OF For personal use only PROGRAM INDICATION PRECLINICAL PHASE 1/2a PHASE 2 MARKET OPPORTUNITY ACTION - ~$20 bn p.a. Targets HIV-1 Vpu HIV-1 Recently reported positive Ph 2 data - >36 m living with HIV-1 ww viroporin protein - 1.1 m in USA BIT225 - ~$20
Slide 8: Biotron – New Approach to Anti-Viral Drug Development
Biotron – New Approach to Anti-Viral Drug Development • Focused on the design and development of a new class of antiviral drugs targeting viral- For personal use only encoded viroporin proteins • Viroporins are present in wide range of viruses: Influenza (M2), HIV-1 (Vpu), HCV (p7), Dengue and West
Slide 9: HIV-1 Eradication
HIV-1 Eradication Current antiretroviral drugs to not cure HIV-1 infection For personal use only • HIV-1 remains hidden in reservoirs, leading to chronic, life-long infection • Invisible to body’s immune defenses • Not sensitive to current anti-HIV-1 drugs • New mode of actions drugs are needed to e
Slide 10: HIV-1 Eradication
HIV-1 Eradication For personal use only BIT225 targets and kills HIV-1 in macrophage cells – these are a key reservoir of infection, even in people taking antiretroviral drugs Mario Stevenson Scientific American 299, 78 - 83 (2008)
Slide 11: BIT225-009 Phase 2 HIV-1 Trial
BIT225-009 Phase 2 HIV-1 Trial 36 HIV +ve, treatment-naïve subjects commencing standard antiretroviral For personal use only treatment (ART). Two arms: Subjects 1. n=9 : 100 mg daily for detailed pharmacokinetic analyses 2. 2. n=27; 200 mg daily for efficacy - Double-blind, placebo-controlled, rando
Slide 12: BIT225 Clears Virus from Macrophage Reservoirs
BIT225 Clears Virus from Macrophage Reservoirs • Cell culture studies showed that BIT225 Infectious HIV-1 Non-infectious HIV-1 For personal use only targets formation of new virus in macrophage cells (Figs A and B) A B • Immunological data from the Phase 2 clinical trial showed a significant immune
Slide 13: Unlocking Value for Other Virus Targets
Unlocking Value for Other Virus Targets For personal use only Biotron’s approach enables the targeting of a wide range of viral diseases; examples include: • Respiratory Viruses such as Respiratory Syncytial Virus (RSV), Influenza, & Coronaviruses (leading cause of “common cold”) • Flaviviruses such
Slide 14: Hepatitis B Virus Program
Hepatitis B Virus Program For personal use only • Hepatitis B virus (HBV) therapeutic space has generated significant interest from pharma & biotech companies • Oct 18 – J&J and Arrowhead in deal worth up to US$3.7 billion • Screening of Biotron’s compound library has identified several compounds wi
Slide 15: Commercialisation & Outlook for 2018/2019 FY
Commercialisation & Outlook for 2018/2019 FY • Aim is to achieve commercial outcomes for the company’s programs For personal use only • Prime focus is partnering the HIV-1 program • Data from the Phase 2 HIV-1 trial to be presented at key conferences, and also shared with potential partners, during
Slide 16: Investment Proposition
Investment Proposition • BIT drugs target high growth, multi-billion dollar markets with defined treatment gaps • HIV-1 Program For personal use only • Significant value created through positive results from the Phase 2 clinical trial (share price up from $0.019 on 27 Sept to $0.16 at close on 24 Oc
Slide 17: Biotron Limited contact details
BIOTRON LIMITED For personal use only (ASX:BIT) Michelle Miller Managing Director mmiller@biotron.com.au www.biotron.com.au